Steve Ryder

4.0k total citations · 2 hit papers
28 papers, 2.8k citations indexed

About

Steve Ryder is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Steve Ryder has authored 28 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Surgery and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Steve Ryder's work include Health Systems, Economic Evaluations, Quality of Life (3 papers), Prostate Cancer Treatment and Research (3 papers) and Lipoproteins and Cardiovascular Health (2 papers). Steve Ryder is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (3 papers), Prostate Cancer Treatment and Research (3 papers) and Lipoproteins and Cardiovascular Health (2 papers). Steve Ryder collaborates with scholars based in United Kingdom, Netherlands and United States. Steve Ryder's co-authors include Jos Kleijnen, Penny Whiting, Kate Misso, Nigel Armstrong, Steven Duffy, Robert Wolff, Sohan Deshpande, Adrían V. Hernández, Shona Lang and Marcello Di Nisio and has published in prestigious journals such as JAMA, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Steve Ryder

26 papers receiving 2.7k citations

Hit Papers

Cannabinoids for Medical Use 2015 2026 2018 2022 2015 2017 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cannabinoids for Medical Use
    2015 1.5k citations Penny Whiting, Robert Wolff et al. JAMA profile →
  2. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review
    2017 351 citations Steve Ryder, Regina Leadley et al. Orphanet Journal of Rare Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steve Ryder United Kingdom 14 1.3k 451 391 304 280 28 2.8k
Joëlle Micallef France 34 898 0.7× 286 0.6× 648 1.7× 396 1.3× 338 1.2× 226 4.0k
Stephen Wright United Kingdom 30 2.7k 2.0× 332 0.7× 270 0.7× 519 1.7× 964 3.4× 67 4.5k
Gianni Tognoni Italy 30 585 0.4× 280 0.6× 412 1.1× 259 0.9× 153 0.5× 103 3.7k
Carlos Martínez United Kingdom 28 410 0.3× 200 0.4× 197 0.5× 197 0.6× 123 0.4× 55 2.9k
Cornelis Kramers Netherlands 26 419 0.3× 328 0.7× 173 0.4× 160 0.5× 125 0.4× 142 2.6k
Birol Emir United States 28 740 0.5× 164 0.4× 165 0.4× 169 0.6× 111 0.4× 133 3.2k
Olivier Ziegler France 30 1.5k 1.1× 476 1.1× 495 1.3× 84 0.3× 372 1.3× 145 4.1k
Shereif H. Rezkalla United States 31 500 0.4× 403 0.9× 476 1.2× 120 0.4× 301 1.1× 69 3.9k
Alec O'connor United States 23 950 0.7× 328 0.7× 221 0.6× 275 0.9× 450 1.6× 48 4.0k
Howard S. Smith United States 41 1.2k 0.9× 292 0.6× 176 0.5× 488 1.6× 269 1.0× 152 4.9k

Countries citing papers authored by Steve Ryder

Since Specialization
Citations

This map shows the geographic impact of Steve Ryder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Ryder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Ryder more than expected).

Fields of papers citing papers by Steve Ryder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Ryder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Ryder. The network helps show where Steve Ryder may publish in the future.

Co-authorship network of co-authors of Steve Ryder

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Ryder. A scholar is included among the top collaborators of Steve Ryder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Ryder. Steve Ryder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Armstrong, Nigel, Jeremy Howick, Susan O’Meara, et al.. (2023). Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 41(4). 353–361. 2 indexed citations
2.
Wijnen, Ben, Robert Wolff, Debra Fayter, et al.. (2022). Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 41(1). 33–42. 6 indexed citations
3.
Grimm, Sabine, Robert Wolff, Mickaël Hiligsmann, et al.. (2021). Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 40(5). 509–518. 1 indexed citations
4.
Armstrong, Nigel, Amit Bahl, Michael Pinkawa, et al.. (2021). SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review. Urology. 156. e74–e85. 49 indexed citations
5.
Armstrong, Nigel, Ruben G.W. Quek, Steve Ryder, et al.. (2020). DNA Damage Repair Gene Mutation Testing and Genetic Counseling in Men With/without Prostate Cancer: a Systematic Review. Future Oncology. 17(7). 853–864. 2 indexed citations
6.
Wijnen, Ben, Nigel Armstrong, Bram Ramaekers, et al.. (2020). Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 38(10). 1043–1053. 8 indexed citations
7.
Grimm, Sabine, Rob Riemsma, Nigel Armstrong, et al.. (2020). Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 39(2). 171–180. 5 indexed citations
8.
Armstrong, Nigel, Nasuh Büyükkaramikli, Rob Riemsma, et al.. (2020). Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 24(51). 1–220. 13 indexed citations
9.
Ryder, Steve, Kathleen M. Fox, Pratik Rane, et al.. (2019). A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective. PharmacoEconomics. 37(7). 895–919. 17 indexed citations
10.
Armstrong, Nigel, Steve Ryder, Carol Forbes, Janine Ross, & Ruben G.W. Quek. (2019). <p>A systematic review of the international prevalence of <em>BRCA </em>mutation in breast cancer</p>. Clinical Epidemiology. Volume 11. 543–561. 163 indexed citations
11.
Armstrong, Nigel, Gill Worthy, Stephanie L. Swift, et al.. (2019). Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin. Current Medical Research and Opinion. 36(1). 101–115. 16 indexed citations
12.
Pouwels, Xavier, Robert Wolff, Bram Ramaekers, et al.. (2018). Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 36(5). 533–543. 5 indexed citations
13.
Ryder, Steve, Regina Leadley, Nigel Armstrong, et al.. (2017). The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet Journal of Rare Diseases. 12(1). 79–79. 351 indexed citations breakdown →
14.
Quek, Ruben G.W., Guillermo Villa, Shravanthi R. Gandra, et al.. (2016). A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. PharmacoEconomics. 35(3). 297–318. 13 indexed citations
15.
Whiting, Penny, Robert Wolff, Sohan Deshpande, et al.. (2015). Cannabinoids for Medical Use. JAMA. 313(24). 2456–2456. 1492 indexed citations breakdown →
16.
Wolff, Robert, Steve Ryder, Alberto Bossi, et al.. (2015). A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. European Journal of Cancer. 51(16). 2345–2367. 63 indexed citations
17.
18.
Whiting, Penny, Maiwenn Al, Marie Westwood, et al.. (2015). Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 19(58). 1–228. 217 indexed citations
19.
Riemsma, Rob, Maiwenn Al, Isaac Corro Ramos, et al.. (2013). SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 17(61). 1–236. 39 indexed citations
20.
Coon, Jo Thompson, G Rogers, Paul Hewson, et al.. (2007). Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technology Assessment. 11(34). 1–206. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joëlle Micallef Breakdown of academic impact, for papers by Stephen Wright Breakdown of academic impact, for papers by Gianni Tognoni Breakdown of academic impact, for papers by Carlos Martínez Breakdown of academic impact, for papers by Cornelis Kramers Breakdown of academic impact, for papers by Birol Emir Breakdown of academic impact, for papers by Olivier Ziegler Breakdown of academic impact, for papers by Shereif H. Rezkalla Breakdown of academic impact, for papers by Alec O'connor Breakdown of academic impact, for papers by Howard S. Smith
Rankless by CCL
2026